211 related articles for article (PubMed ID: 28641702)
1. [Prospect and Current Situation of Immune Checkpoint Inhibitors
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].
Wang H; Yu X; Fan Y
Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):427-432. PubMed ID: 28641702
[TBL] [Abstract][Full Text] [Related]
2. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
[TBL] [Abstract][Full Text] [Related]
4. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
Melosky B; Chu Q; Juergens RA; Leighl N; Ionescu D; Tsao MS; McLeod D; Hirsh V
Cancer Treat Rev; 2018 Apr; 65():65-77. PubMed ID: 29567557
[TBL] [Abstract][Full Text] [Related]
5. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.
Giri A; Walia SS; Gajra A
Rev Recent Clin Trials; 2016; 11(4):297-305. PubMed ID: 27457350
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint modulation for non-small cell lung cancer.
Soria JC; Marabelle A; Brahmer JR; Gettinger S
Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?
Gray SG; Cuffe S; Finn SP
J Thorac Oncol; 2016 Nov; 11(11):e142-e144. PubMed ID: 27770977
[No Abstract] [Full Text] [Related]
10. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
Lee CK; Man J; Lord S; Links M; Gebski V; Mok T; Yang JC
J Thorac Oncol; 2017 Feb; 12(2):403-407. PubMed ID: 27765535
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
Helissey C; Champiat S; Soria JC
Curr Opin Oncol; 2015 Mar; 27(2):108-17. PubMed ID: 25602683
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
Remon J; Besse B
Curr Opin Oncol; 2017 Mar; 29(2):97-104. PubMed ID: 28059852
[TBL] [Abstract][Full Text] [Related]
14. Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?
Remon J; Hendriks L; Aspeslagh S; Besse B
J Thorac Oncol; 2019 Oct; 14(10):1701-1703. PubMed ID: 31420287
[No Abstract] [Full Text] [Related]
15. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
16. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
Dempke WC; Sellmann L; Fenchel K; Edvardsen K
Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
19. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Remon J; Besse B; Soria JC
BMC Med; 2017 Mar; 15(1):55. PubMed ID: 28285592
[TBL] [Abstract][Full Text] [Related]
20. MEDI 4736 (durvalumab) in non-small cell lung cancer.
Jeanson A; Barlesi F
Expert Opin Biol Ther; 2017 Oct; 17(10):1317-1323. PubMed ID: 28705024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]